SEC Form 4 · accession 0001192482-17-000304
COLLEGIUM PHARMACEUTICAL, INC · COLL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Yasunori Kaneko
10% Owner
Period of report
Dec 5, 2017
Accepted (ET)
Dec 7, 2017 · 7:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001267565
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Dec 5, 2017 | J | 800,000 | $0.00 | D | 2,149,916 | I | By Skyline Venture Partners V, L.P. |
| Common Stock | Dec 5, 2017 | J | 270 | $0.00 | A | 270 | I | By the Kaneko Family Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents a pro rata in-kind distribution of the shares by Skyline Venture Partners V, L.P. without consideration to its limited and general partners.
- F2The shares are held by Skyline Venture Partners V, L.P. The general partner of Skyline Venture Partners V, L.P. is Skyline Venture Management V, LLC. John G. Freund and Yasunori Kaneko are managers of Skyline Venture Management V, LLC. These individuals share voting and investment power over the shares held by Skyline Venture Management, LLC. Dr. Kaneko disclaims beneficial ownership of all the shares held by Skyline Venture Partners V, L.P. except to the extent of his proportionate pecuniary interest therein.
- F3Represents a pro rata in-kind distribution of the shares by Skyline Venture Partners V, L.P. without consideration to the reporting person.